Health Sciences TrustJAFMX
Type
Mutual fund
Peer group
US equity: Healthcare
Net assets
$227.2M
Expense ratio
0.99%
1-year return
+12.9%
3 years, a year
+6.8%
5 years, a year
+3.1%
Holdings
175
What it aims to do.
To seek long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly and Company | 10.20% |
| TMO Thermo Fisher Scientific Inc. | 4.12% |
| ISRG Intuitive Surgical Inc. | 3.71% |
| SYK Stryker Corporation | 3.52% |
| MRK Merck and Co. Inc. | 3.48% |
| AZN AstraZeneca PLC | 3.22% |
| UNH UnitedHealth Group Incorporated | 3.13% |
| ARGX argenx SE | 2.99% |
| ABBV AbbVie Inc. | 2.88% |
| REGN Regeneron Pharmaceuticals Inc. | 2.69% |
More on JAFMX.
- JAFMX overview
- JAFMX holdings
- JAFMX risk
- JAFMX costs
- JAFMX money in and out
- JAFMX share classes
- Compare JAFMX with other funds
Returns after fees, from the fund's SEC filings up to Mar 2026. Past returns are not a promise. Not financial advice.